Nizatidine


Description

A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.

Read more

Pharmacology

Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer... Read more

Pharmacodynamic

Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, partic... Read more

Mechanism of action

Nizatidine competes with histamine for binding at the H2-receptors on the gastric basolat... Read more

Absorption

Rapid (bioavailability of nizatidine exceeds 70%)

Protein binding

35%

Volume of distribution

0.8 to 1.5 L/kg

Clearance

40-60 L/h7 – 14 L/h [functionally anephric patients]

Half life

1-2 hours

Route of elimination

Information currently not available.

Toxicity

Oral, rat LD50: 301 mg/kg. Symptoms of overdose include cholinergic-type effects includin... Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Headache US
  • Kind: experimental
    • Percent: 17%
  • Kind: placebo
    • Percent: 16%
  • Clinical Trial
    Abdominal Pain US
  • Kind: experimental
    • Percent: 8%
  • Kind: placebo
    • Percent: 13%
  • Clinical Trial
    Rhinitis US
  • Kind: experimental
    • Percent: 10%
  • Kind: placebo
    • Percent: 10%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 7%
  • Clinical Trial
    Diarrhea US
  • Kind: experimental
    • Percent: 7%
  • Kind: placebo
    • Percent: 7%
  • Clinical Trial
    Vomiting US
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 6%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 4%
  • Clinical Trial
    Flatulence US
  • Kind: experimental
    • Percent: 5%
  • Kind: placebo
    • Percent: 5%
  • Clinical Trial
    Pain US
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 4%
  • Clinical Trial
    Constipation US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 4%
  • Clinical Trial
    Dyspepsia US
  • Kind: experimental
    • Percent: 4%
  • Kind: placebo
    • Percent: 4%
  • Clinical Trial
    Asthenia US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Back Pain US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Pharyngitis US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Insomnia US
  • Kind: experimental
    • Percent: 3%
  • Kind: placebo
    • Percent: 3%
  • Clinical Trial
    Chest Pain US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Infection US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Myalgia US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Anorexia US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Nausea and vomiting US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Surgical Procedure US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Fever US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Increased cough US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Rash US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Pruritus US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Sinusitis US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Abnormal dreams US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Somnolence US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 2%
  • Clinical Trial
    Anxiety US
  • Kind: experimental
    • Percent: 2%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Tooth disorder US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Gastrointestinal Disorder US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Dry Mouth US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Accidental injury US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Amblyopia US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Nervousness US
  • Kind: experimental
    • Percent: 1%
  • Kind: placebo
    • Percent: 1%
  • Clinical Trial
    Elevated Liver Enzymes US
    Clinical Trial
    Hepatitis US
    Clinical Trial
    Jaundice US
    Clinical Trial
    Cholestatic injury US
    Clinical Trial
    Hepatocellular Injury US
    Clinical Trial
    Asymptomatic ventricular tachycardia US
    Clinical Trial
    Mental confusion US
    Clinical Trial
    Impotence US
    Clinical Trial
    Hyperuricemia US
    Clinical Trial
    Bronchospasm US
    Clinical Trial
    Anaphylaxis US
    Clinical Trial
    Vasculitis US
    Clinical Trial
    Exfoliative dermatitis US
    Clinical Trial
    Serum sickness-like reactions US
    Clinical Trial
    Eosinophilia US
    Clinical Trial

    Contraindications

    • Hypersensitivity:
      • H2 Antagonists
    • Regions: US

    Food Interactions

    • Avoid alcohol.
    • Avoid excessive quantities of coffee or tea (Caffeine).
    • Do not take Aluminum or magnesium antacids or supplements while on this medication.
    • May take Vitamin D.
    • No iron, zinc or fluoride within 2 hours of taking this medication.
    • Take without regard to meals.

    Interactions

    Type in a drug name to check for interaction with Nizatidine

    2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Nizatidine.
    2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Nizatidine.
    4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Nizatidine.
    Nizatidine can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
    The serum concentration of Nizatidine can be increased when it is combined with Abemaciclib.
    The serum concentration of Acebutolol can be increased when it is combined with Nizatidine.
    The serum concentration of Nizatidine can be increased when it is combined with Acetaminophen.
    The risk or severity of adverse effects can be increased when Nizatidine is combined with Acetylcholine.
    The serum concentration of Acetylsalicylic acid can be increased when it is combined with Nizatidine.
    The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Acipimox.
    The therapeutic efficacy of Aclidinium can be decreased when used in combination with Nizatidine.
    The serum concentration of Nizatidine can be increased when it is combined with Afatinib.
    The therapeutic efficacy of Agmatine can be decreased when used in combination with Nizatidine.
    Nizatidine can cause a decrease in the absorption of Albaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
    The serum concentration of Nizatidine can be increased when it is combined with Albendazole.
    Nizatidine may decrease the neuromuscular blocking activities of Alcuronium.
    The serum concentration of Aldosterone can be increased when it is combined with Nizatidine.
    The serum concentration of Nizatidine can be increased when it is combined with Alectinib.
    The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Alendronic acid.
    The serum concentration of Nizatidine can be increased when it is combined with Alfentanil.

    References

      Information currently not available.

    Recent Questions